Literature DB >> 17287279

Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

Michael S Mitchell1, Ellen T Bodine, Shawn Hill, Gerald Princler, Patricia Lloyd, Hiroaki Mitsuya, Masao Matsuoka, David Derse.   

Abstract

It is well established that cell-free infection with human T-cell leukemia virus type 1 (HTLV-1) is less efficient than that with other retroviruses, though the specific infectivities of only a limited number of HTLV-1 isolates have been quantified. Earlier work indicated that a post-entry step in the infectious cycle accounted for the poor cell-free infectivity of HTLV-1. To determine whether variations in the pol gene sequence correlated with virus infectivity, we sequenced and phenotypically tested pol genes from a variety of HTLV-1 isolates derived from primary sources, transformed cell lines, and molecular clones. The pol genes and deduced amino acid sequences from 23 proviruses were sequenced and compared with 14 previously published sequences, revealing a limited number of amino acid variations among isolates. The variations appeared to be randomly dispersed among primary isolates and proviruses from cell lines and molecular clones. In addition, there was no correlation between reverse transcriptase sequence and the disease phenotype of the original source of the virus isolate. HTLV-1 pol gene fragments encoding reverse transcriptase were amplified from a variety of isolates and were subcloned into HTLV-1 vectors for both single-cycle infection and spreading-infection assays. Vectors carrying pol genes that matched the consensus sequence had the highest titers, and those with the largest number of variations from the consensus had the lowest titers. The molecular clone from CS-1 cells had four amino acid differences from the consensus sequence and yielded infectious titers that were approximately eight times lower than those of vectors encoding a consensus reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287279      PMCID: PMC1900182          DOI: 10.1128/JVI.02660-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Defective and wild-type human T-cell leukemia virus type I proviruses: characterization of gene products and trans-interactions between proviruses.

Authors:  M Shuh; S A Hill; D Derse
Journal:  Virology       Date:  1999-09-30       Impact factor: 3.616

Review 2.  Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response.

Authors:  Susan J Marriott; Oliver John Semmes
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

3.  X-I and X-II open reading frames of HTLV-I are not required for virus replication or for immortalization of primary T-cells in vitro.

Authors:  D Derse; J Mikovits; F Ruscetti
Journal:  Virology       Date:  1997-10-13       Impact factor: 3.616

4.  Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas.

Authors:  H Ellerbrok; C Fleischer; M Salemi; P Reinhardt; W D Ludwig; A M Vandamme; G Pauli
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-01       Impact factor: 2.205

Review 5.  Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses.

Authors:  J P Slattery; G Franchini; A Gessain
Journal:  Genome Res       Date:  1999-06       Impact factor: 9.043

Review 6.  Human T-lymphotropic virus type I infection.

Authors:  A Manns; M Hisada; L La Grenade
Journal:  Lancet       Date:  1999-06-05       Impact factor: 79.321

7.  Molecular phylogeny of human T-cell leukemia virus type I and II of Amerindians in Colombia and Chile.

Authors:  T Miura; M Yamashita; V Zaninovic; L Cartier; J Takehisa; T Igarashi; E Ido; T Fujiyoshi; S Sonoda; K Tajima; M Hayami
Journal:  J Mol Evol       Date:  1997       Impact factor: 2.395

8.  Evidence for a post-Columbian introduction of human T-cell lymphotropic virus [type I] [corrected] in Latin America.

Authors:  S Van Dooren; E Gotuzzo; M Salemi; D Watts; E Audenaert; S Duwe; H Ellerbrok; R Grassmann; E Hagelberg; J Desmyter; A M Vandamme
Journal:  J Gen Virol       Date:  1998-11       Impact factor: 3.891

9.  HTLV-I-associated myelopathy/tropical spastic paraparesis in the United States.

Authors:  R S Janssen; J E Kaplan; R F Khabbaz; R Hammond; R Lechtenberg; M Lairmore; M A Chiasson; A Punsalang; B Roberts; R R McKendall
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

10.  Two new human T-lymphotropic virus type I phylogenetic subtypes in seroindeterminates, a Mbuti pygmy and a Gabonese, have closest relatives among African STLV-I strains.

Authors:  M Salemi; S Van Dooren; E Audenaert; E Delaporte; P Goubau; J Desmyter; A M Vandamme
Journal:  Virology       Date:  1998-07-05       Impact factor: 3.616

View more
  11 in total

1.  TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax.

Authors:  Guangyong Ma; Jun-ichirou Yasunaga; Hirofumi Akari; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

2.  The role of ITCH protein in human T-cell leukemia virus type 1 release.

Authors:  Batsukh Dorjbal; David Derse; Patricia Lloyd; Ferri Soheilian; Kunio Nagashima; Gisela Heidecker
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

3.  Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo.

Authors:  Guangyong Ma; Jun-Ichirou Yasunaga; Koichi Ohshima; Tadashi Matsumoto; Masao Matsuoka
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

4.  APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo.

Authors:  Jun Fan; Guangyong Ma; Kisato Nosaka; Junko Tanabe; Yorifumi Satou; Atsushi Koito; Simon Wain-Hobson; Jean-Pierre Vartanian; Masao Matsuoka
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

5.  Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.

Authors:  Emanuela Balestrieri; Claudia Matteucci; Arianna Ascolani; Anna Piperno; Roberto Romeo; Giovanni Romeo; Ugo Chiacchio; Antonio Mastino; Beatrice Macchi
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

6.  Improvement of HIV-1 and Human T Cell Lymphotropic Virus Type 1 Replication-Dependent Vectors via Optimization of Reporter Gene Reconstitution and Modification with Intronic Short Hairpin RNA.

Authors:  Anastasia Shunaeva; Daria Potashnikova; Alexey Pichugin; Alexandra Mishina; Alexander Filatov; Olga Nikolaitchik; Wei-Shau Hu; Dmitriy Mazurov
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

7.  The role of WWP1-Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1.

Authors:  Gisela Heidecker; Patricia A Lloyd; Ferri Soheilian; Kunio Nagashima; David Derse
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

8.  How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy.

Authors:  Amandine Pasquier; Sandrine Alais; Loic Roux; Maria-Isabel Thoulouze; Karine Alvarez; Chloé Journo; Hélène Dutartre; Renaud Mahieux
Journal:  Front Microbiol       Date:  2018-03-13       Impact factor: 5.640

9.  M-Sec induced by HTLV-1 mediates an efficient viral transmission.

Authors:  Masateru Hiyoshi; Naofumi Takahashi; Youssef M Eltalkhawy; Osamu Noyori; Sameh Lotfi; Jutatip Panaampon; Seiji Okada; Yuetsu Tanaka; Takaharu Ueno; Jun-Ichi Fujisawa; Yuko Sato; Tadaki Suzuki; Hideki Hasegawa; Masahito Tokunaga; Yorifumi Satou; Jun-Ichirou Yasunaga; Masao Matsuoka; Atae Utsunomiya; Shinya Suzu
Journal:  PLoS Pathog       Date:  2021-11-29       Impact factor: 6.823

10.  LKB1 tumor suppressor and salt-inducible kinases negatively regulate human T-cell leukemia virus type 1 transcription.

Authors:  Hei-Man Vincent Tang; Wei-Wei Gao; Ching-Ping Chan; Yeung-Tung Siu; Chi-Ming Wong; Kin-Hang Kok; Yick-Pang Ching; Hiroshi Takemori; Dong-Yan Jin
Journal:  Retrovirology       Date:  2013-04-11       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.